remibrutinib
novartis
['remibrutinib']
data from a phase 2 rct of remibrutinib (bruton's tyrosine kinase inhibitor; lou064) in sj gren s syndrome from thomas d rner shows improvement in essdai and salivary flow with remibrutinib compared with placebo (wk 24), but no difference in esspri. #acr22 
The #LancetRheumatology is a clinical #rheumatology journal publishing innovative & practice-changing research & opinion across all #rheumatic & #MSK disorders